PharmatrophiX — Aided by C2N Diagnostics — Finds That Its Small-Molecule Drug LM11A-31 Blocked the Rise of an Alzheimer’s Disease Tau Pathology Biomarker
New Phase 2a analysis presented at the Clinical Trials on Alzheimer's Disease conference shows LM11A-31 prevented the increase of a…
Read More




